CtDNA-guided Maintenance Therapy in Pancreatic Cancer

This trial uses a blood test called ctDNA (circulating tumor DNA — tiny fragments of cancer DNA that float in your blood) to guide follow-up treatment for people with pancreatic cancer who have had surgery. If the ctDNA test shows lingering cancer signals after surgery, targeted maintenance chemotherapy is given; if not, treatment may be skipped. This approach aims to personalise treatment and avoid unnecessary chemotherapy. **You may be eligible if...** - You have been diagnosed with pancreatic duct cancer with no distant spread - You have recently had a successful surgery to remove the tumor (R0 resection) - You have not received prior chemotherapy or radiation for this cancer - Your overall health is adequate (ECOG 0–1) and you can tolerate chemotherapy **You may NOT be eligible if...** - Your cancer has already spread to distant organs - You have significant organ problems that would make chemotherapy unsafe - You have had another cancer in the past 5 years (some exceptions apply) - You have uncontrolled hepatitis B, hepatitis C, or HIV infection Talk to your doctor to see if this trial is right for you.